**‘Real-world’ compensatory behaviour with low nicotine concentration e-liquid: subjective effects and nicotine, acrolein and formaldehyde exposure**

Dr. Lynne Dawkins1, Dr. Sharon Cox1, Dr. Maciej Goniewicz2, Professor. Hayden McRobbie3, Catherine Kimber4, Dr. Mira Doig5, Dr. Leon Kośmider6

1 LD Corresponding author: Centre for Addictive Behaviours Research, School of Applied Sciences, London South Bank University, 103 Borough Rd. London, UK. [dawkinl3@lsbu.ac.uk](mailto:dawkinl3@lsbu.ac.uk); orcid.org/0000-0003-1236-009X

2 Roswell Park Cancer Institute, Department of Health Behavior, Elm and Carlton Streets, Buffalo, NY 14263, USA.

3Queen Mary University of London, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London, UK.

4University of East London, School of Psychology, College of Applied Health and Communities,

Waters Lane, London, UK.

5ABS Laboratories Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX UK.

6 Department of Pharmaceutics, School of Pharmacy, affiliated with the Center for the Study of Tobacco Products, Virginia Commonwealth University, 410N 12th Street, Box 980533, Richmond, VA 23298-0533, USA.

**Running head:** Real-world compensatory e-cigarette behaviour

**Word count:** 3999

**Declarations of competing interest:** This study was support by grant C50878/A21130 from Cancer Research UK. LD has conducted research for independent electronic cigarette companies.  These companies had no input into the design, conduct or write up of the projects.  She has also acted as a consultant for the pharmaceutical industry and as an expert witness in a patent infringement case (2015).MG received a research grant from Pfizer and serves on an advisory board to Johnson & Johnson, manufacturers of smoking cessation medications. HM has received honoraria for speaking at research symposia and received benefits in kind and travel support from, and has provided consultancy to, the manufacturers of smoking cessation medications. LK is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number P50DA036105 and the Center for Tobacco Products of the U.S. Food and Drug Administration. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH or the FDA. LK was also an employee of the Institute of Occupational Medicine and Environmental Health. One of the institute’s objectives is outsourcing for the industrial sector, including manufacturers of e-cigarettes. SC, CK & MD have no conflicts of interest to declare.

**Abstract**

**Aims:**  To compare the effects of i) high versus low nicotine concentration e-liquid, ii) fixed versus adjustable power and iii) the interaction between the two on: a) vaping behaviour, b) subjective effects, c) nicotine intake, and d) exposure to acrolein and formaldehyde in e-cigarette users vaping in their everyday setting.

**Design**: Counterbalanced, repeated measures with four conditions: i) low nicotine (6 mg/mL)/fixed power; ii) low nicotine/adjustable power; iii) high nicotine (18 mg/mL)/fixed power; iv) high nicotine/adjustable power.

Setting: London and the South East, England.

Participants: Twenty experienced e-cigarette users (recruited between September 2016 and February 2017) vaped ad libitum using an eVic Supreme™ with a ‘Nautilus Aspire’ tank over four weeks (one week per condition).

**Measurements:** Puffing patterns (daily puff number [PN], puff duration [PD], inter-puff interval [IPI]), mL of e-liquid consumed, changes to power (where permitted), and subjective effects (urge to vape, nicotine withdrawal symptoms) were measured in each condition.  Nicotine intake was measured via salivary cotinine.  3-hydroxypropylmercapturic acid (3-HPMA), a metabolite of the toxicant acrolein, and formate, a metabolite of the carcinogen formaldehyde, were measured in urine.

**Findings:**  There was a significant nicotine concentration x power interaction for PD (p<0.01). PD was longer with low nicotine/fixed power compared with i) high nicotine/fixed power (p< 0.001 and ii) low nicotine/adjustable power (p< 0.01).  PN and liquid consumed were higher in the low versus high nicotine condition (main effect of nicotine, p<0.05).  Urge to vape and withdrawal symptoms were lower, and nicotine intake was higher, in the high nicotine condition (main effects of nicotine: p<0.01).  Whilst acrolein levels did not differ, there was a significant nicotine x power interaction for formaldehyde (p<0.05).

**Conclusions:** Use of a lower nicotine concentration e-liquid was may be associated with compensatory behaviour (e.g., higher number and duration of puffs) and increases in negative affect, urge to vape, and formaldehyde exposure.

Keywords: E-cigarette, puffing patterns, compensatory behaviour, subjective effects, nicotine, acrolein, formaldehyde

**Introduction**

Awareness and use of electronic cigarettes (e-cigarettes) has rapidly increased over recent years, with an estimated 23.1 million smokers in the EU reporting ever trying an e-cigarette in 2012 [1] and 12.9 million people using e-cigarettes in the US in 2014. [2]. In the UK, an estimated 2.9 million people currently use e-cigarettes and for the first time in 2017, there are more ex-smokers using e-cigarettes (52%) than dual users (45% [3]). The most commonly cited reason for use is to quit smoking and increasing evidence suggests that e-cigarette use may be an effective tool for this [4-6].

Nicotine delivery from e-cigarettes varies considerably and depends on a variety of factors: the nicotine concentration in the e-liquid [7], the type and power of the device and settings [8-10] as well as user characteristics including puffing patterns [9,11,12]. Over-time, e-cigarette users (vapers) tend to lower the nicotine concentration in their e-liquid [13,14]. This may be due to: the belief that it is healthier; to allow changes to the device/tank (e.g. sub-ohming - using an atomiser coil with a resistance of < 1 Ohm with increased power); or to wean off e-cigarette/nicotine use entirely. However, a reduction in nicotine intake may not actually follow a reduction in nicotine e-liquid concentration if users engage in compensatory puffing such as increasing the total puff number, or taking longer puffs [12,15]. In fact, in 98 vapers tested at baseline and 8 months later, whilst average nicotine concentration in e-liquid decreased from 11 to 6 mg/mL, salivary cotinine levels remained stable [13]. Hence, vapers’ may self-titrate to a level of satisfaction which is optimal to their needs when adjusting to a lower nicotine concentration e-liquid.

Compensatory puffing behaviour is seen in tobacco smoking [16-19], with smokers achieving 60-80% of their optimal nicotine levels by engaging in this practice (i.e. by taking longer, larger volume and more frequent puffs) when switching to lower nicotine yield cigarettes [20]. To date, there are only a few studies on compensatory puffing in e-cigarette use. Ramoa et al., [15] reported longer and deeper puffs in vapers using a 0 compared with a 36 mg/mL nicotine e-liquid and, in a small laboratory based study (*N*=11), Dawkins et al., [12] observed compensatory behaviour in vapers using 6 mg/mL compared with 24 mg/mL e-liquid via more frequent and longer puffs resulting in a doubling of e-liquid consumed. In a very recent report, compensatory puffing (increased puff number and puff duration) was also observed when device power was set at 6W compared with 10W [21]. Aside from puffing behaviour, vapers may engage in other forms of compensatory behaviour by adjusting the settings on the device itself. Newer generation devices now commonly house a control head allowing air-flow, voltage or wattage to be adjusted. Anecdotal reports suggest that use of lower nicotine concentration e-liquids is accompanied by a lower atomiser resistance and upward voltage or wattage adjustment. This increases the overall power output of the device which in turn increases aerosol production. This form of behaviour compensation however, has received no attention in the extant empirical literature.

Compensatory behaviour including more frequent and longer puffs and increasing power can increase the temperature of the coil at which glycerine and propylene glycol (solvents used in e-liquids) undergo decomposition to carbonyl compounds [22]. This in turn may increase exposure to carcinogens such as formaldehyde, acetaldehyde and acrolein. Four studies have explored biomarker levels in human vaper’s saliva or urine and have reported a more favourable toxicity profile than for tobacco smokers under normal usage conditions for polycyclic aromatic hydrocarbons (PAHs), tobacco specific nitrosamines (TSNAs) and other carcinogens including acrolein [23]. Reduced TSNAs, PAHs and volatile organic compounds (VOCs) have also been found in smokers who switched to vaping over a 2-4 week period compared to those who continued smoking whilst nicotine exposure remained unchanged [24,25]. In a recent study comparing tobacco smokers with e-cigarette-only and nicotine replacement therapy (NRT)-only users, carcinogens and toxicants (TSNAs, VOC) were lower in both e-cigarette and NRT users compared with tobacco smokers [26]. To date, no studies have explored biomarkers of exposure to the known human carcinogen formaldehyde or explored the effect of compensatory behaviour on carcinogen exposure.

The paucity of research on compensatory behaviour in e-cigarette use makes it difficult to generate clear evidenced-based health messages which can inform the public on the possible subjective, biological and toxicant effects of increased usage. Currently, the laboratory based studies provide some evidence of compensatory puffing but these have used restrictive behavioural parameters which may not reflect true user behaviour. In reality, vapers are likely to adjust the power (wattage) on their devices (where device type allows) when switching to lower nicotine concentration e-liquids according to personal preference and current needs. Vapers can adjust the power either by increasing battery output voltage or replacing the atomizer with a heating element of lower resistance (for example in ‘sub-ohming’). In most cases, given that the atomizer resistance stays the same, by increasing voltage, vapers are increasing the overall power (wattage) of the device.

In the present study, participants vaped *ad libitum* using an eVic Supreme™ with a ‘Nautilus Aspire’ tank over four weeks (one week per conditions): i) low nicotine (6 mg/mL)/fixed power; ii) low nicotine/adjustable power; iii) high nicotine (18 mg/mL)/fixed power; iv) high nicotine/adjustable power. Although it was the voltage rather than the wattage that participants adjusted, given that the atomiser resistance remained the same, increasing voltage results in an overall power increase, hence we refer to changes to power throughout. The aims were: 1) to compare the effects of nicotine concentration and power setting on: a) puffing behaviour (puff number, puff duration, inter-puff interval [IPI]); 2) product use (e-liquid consumed and voltage adjustment); b) subjective effects (urge to vape, nicotine withdrawal symptoms, and positive and negative effects); and c) nicotine delivery, acrolein and formaldehyde exposure. We hypothesised significant nicotine concentration x power interactions; i.e. the lower nicotine concentration e-liquid, especially in combination with adjustable power, would be associated with compensatory behaviour (increased puff number, longer puff duration and higher voltage [where changes to power are permitted]), reduced positive subjective effects, and increased toxicant exposure.

**Methods**

**Design and ethical approval**

The study was approved by London South Bank University ethics committee (UREC 1604) and conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki. Participants provided written informed consent to take part and for the study to be written up for publication. A randomised, within-participants counterbalanced design with 4 conditions (low nicotine/fixed power; high nicotine/fixed power; low nicotine/adjustable power; high nicotine/adjustable power) was used. Twenty-two participants were recruited via social media and University advertising between September 2016 and February 2017. Two withdraw during week 1 but as per protocol [27] we continued to recruit until 20 participants had completed all four conditions. Participants were asked to vape *ad libitum* using an eVic Supreme™ with a ‘Nautilus Aspire’ tank over four weeks (one week per condition). The sample size was based on puff number and puff duration results from our pilot study and from Dawkins et al. [12] where effect sizes of between d=0.74 and d=0.79 were found for puff number and between d=0.84 and d=1.09 for puff duration. A sample of between N=14 to 19 for puff number and between N=11 to 17 for puff duration would allow us to detect effects at p<0.05 with more than 90% power.

**Procedure**

The published protocol describes the procedure and measures in detail [27]. Participants were eligible to participate if they were: aged 18+; experienced and exclusive daily e-cigarette user (daily use for > 3 months); currently using a second or third generation e-cigarette; using ≥12 mg/mL nicotine concentration e-liquid (to ensure participants were familiar with higher levels of nicotine) or sub-ohming (any nicotine level); non-smoker as confirmed by carbon monoxide (CO) levels in expired breath of ≤ 10 ppm. We excluded pregnant or lactating females, current smokers or users of marijuana or other illicit drugs and those with a serious medical condition (self-reported). Participants met with the researcher on five separate occasions (at baseline and the end of each of the 4 experimental conditions). At baseline participants provided written informed consent, demographic characteristics and smoking/vaping history then sampled four e-liquids (tobacco, fruit, bakery and menthol) selecting one to be used for the next 4 weeks. Participants were provided with an eVic Supreme™ by Joytech fitted with a ‘Nautilus Aspire’ tank housing a BVC atomizer (1.6 Ohm) and seven 10ml bottles of e-liquid for the week (6 mg/mL or 18 mg/mL according to condition).

For each puff, the eVic records: time of the puff, puff length (in seconds), atomiser resistance, voltage and wattage. To ensure device familiarity before changes were permitted, the first two weeks were always fixed at 4.0V (10W) with the widest air-flow setting on the tank. Changes to voltage and airflow were permitted during the last two weeks. Participants could adjust the airflow by turning a horizontal dial on the tank. However, no changes to airflow were made so this is not reported further. Voltage could be adjusted (between 3.0 and 6.0V) by turning a dial under the display unit on the eVic. Given that the atomiser resistance was fixed at 1.6 Ohm, adjusting the voltage upwards results in increased wattage (overall power output). Participants were randomly assigned to start on either 6 mg/mL or 18 mg/mL nicotine concentration e-liquid giving rise to four possible orders. Participants were instructed to refrain from using their own devices and e-liquids for the duration of the study.

At baseline and each follow up time point, breath CO samples were taken (to confirm that participants had not recently smoked) and saliva and urine were provided and sent to Advanced Bioanalytical Service (ABS) Laboratories Ltd, where they were frozen at -20° until assayed. Saliva was assayed for cotinine [28], to determine nicotine intake. Urine was assayed for 3-HPMA to estimate acrolein exposure [24] and formate for formaldehyde exposure [29]. Both were adjusted for creatinine concentration.

At all five visits, participants reported their urge to vape, withdrawal symptoms and positive and negative effects over the last week. At the end of each condition, puffing and power data was downloaded from the device using myVapor™ software. Volume of e-liquid used was recorded based on participant self-report. At the end of the study participants were debriefed, thanked for their participation and compensated £60 for their time and travel.

**Measures**

Demographic and smoking and vaping related information were collected at baseline including: length of time since quitting smoking; e-cigarette device used; estimated daily volume of e-liquid consumed; nicotine concentrations used; self-rated addiction to e-cigarettes (0-100%); and E-cigarette dependence (measured using the Penn State E-cigarette dependence index)[30].

At all five visits, participants completed a modified version of the Mood and Physical Symptoms Scale [31] for urge to vape and nicotine withdrawal symptoms. Time spent with urges over the past week was rated from 0=not at all to 5=all the time, strength of urges were rated from 0=no urges to 5=extremely strong, and withdrawal symptoms were rated from 1=not at all to 5=extremely. Positive (e.g. hit, satisfaction) and negative (nausea, headache) effects were rated on visual analogue scales (VAS) ranging from 0-100%; [11].

**Data Analysis**

**Puffing Topography and User Behaviour**

Data from the first/last day of each condition was excluded from analysis as a) user behaviour on the first day is likely to reflect familiarity and adjustment to the device; and b) these represented condition change-over days. Puffing data was screened and all button presses <1 second (false button presses or non-starts) were deleted. Puffing data from one participant was lost due to a problem with the device. The mean number of days per condition was 6 but due to appointment re-arrangements, occasional use of own device, or days of non-use (due to flights, hospital admission), this ranged from 4 to 13. Averages (mean for voltage, daily puff number, puff duration and liquid consumption and median for IPI) for each condition were computed by summing the data points for that variable and dividing by the number of compliant days in that condition.

Data were analysed using SPSS v.21. Distributions for most variables were normal although withdrawal symptoms, negative effects, 3-HPMA and formate were positively skewed. Repeated measures Analysis of Variance with nicotine concentration (6 vs. 18 mg/mL) and power type (fixed [F] vs. adjustable [A]) were conducted for each variable (except voltage which was fixed in 2/4 conditions). Order of testing was added as an additional between-subjects variable but is only mentioned where a significant main effect or interaction was found. The accepted alpha level was p<0.05. Where significant nicotine x power interactions were found, post-hoc paired sample t-tests were conducted (for 6F vs. 6A; 18F vs. 18A; 6F vs. 18A and 6A vs. 18A as appropriate). The alpha level for post-hoc tests was subjected to a Bonferroni adjustment (0.05/4); the accepted alpha level was therefore 0.01. ANOVA results for the interaction and main effects of nicotine concentration and power are displayed in Table 2. Post hoc test statistics and any order effects are included in the text below.

**Results**

Participants’ characteristics are shown in Table 1. On average, participants had quit smoking for 26 months, had a mean score of 12.05 on the Penn State E-cigarette dependence index and used a mean of 6.57 ml of e-liquid a day. Baseline salivary cotinine levels ranged from 39 to 719 ng/mL.

**Puffing Topography**

Puffing topography data for each condition are presented in Table 2 (individual puffing patterns are available in the supplementary information).

*Puff Number*

The nicotine x power interaction was not statistically significant but there was a main effect of nicotine with a higher puff number in the 6 vs 18 mg/mL nicotine condition.

*Puff Duration*

There was a significant nicotine concentration x power interaction. Puff duration was significantly longer with 6 compared with 18 mg/mL nicotine e-liquid in the fixed power condition (6F vs. 18F: t18 = 5.26, p = 0.000, mean difference = 0.85, 95% CI – 0.51 – 1.19) and longer with 6 fixed vs 6 adjustable power (t18 = 3.15, p = 0.006, mean difference = 0.66, 95% CI = 0.22 – 1.09). There was also a significant setting x order interaction (F3,15 = 4.61, p = 0.02, ηp2 = 0.48) with those starting and finishing on 6mg/mL demonstrating a shorter puff duration when settings were user-defined.

*Inter-Puff Interval (IPI)*

IPI was calculated from information on puff timings in each condition. The median, rather than mean, IPI was taken due to the highly skewed data which included long periods of inactivity/non-use (presumably due to sleeping or working where vaping is not permitted). IPI could not be calculated for some conditions for two participants due to corrupted data files which distorted puff times.

The nicotine x power interaction was statistically significant. Inspection of Table 2 reveals that IPI was shortest under the 6 mg/mL fixed condition and was similar under all other conditions. These differences however, fell short of statistical significance in post-hoc tests.

**Product Use**

*E-Liquid Consumption*

There was no nicotine x power interaction although a significantly greater volume (mL) of e-liquid per day was consumed in the 6 vs 18 mg/mL nicotine condition (main effect of nicotine).

*Changes to Power Setting (Voltage)*

When participants were permitted to adjust the power, compared to the fixed 4V (10W) condition, 13 increased the voltage, 2 made no changes and 4 decreased it in the 6 mg/mL nicotine condition. In the 18 mg/mL nicotine condition, 6 increased the voltage, 5 made no changes and 7 decreased it. Overall, mean voltage was higher in the adjustable (Mean = 4.39, SD = 0.75) compared with the fixed (4V) power condition; participants increased the voltage by a mean of 0.5v (95% CI = 0.17 – 0.84) in the low nicotine condition and 0.3v (95% CI = 0.12 – 0.65) in the high condition.

**Subjective Effects**

Mean scores for subjective effects in each condition are presented in Table 2.

*Urge to Vape*

Although there was no significant nicotine concentration x power interaction for either urge to vape or strength of urges,both were significantly higher in the 6 compared with the 18 mg/mL nicotine condition (main effect of nicotine).

*Withdrawal Symptoms*

The nicotine x power interaction was not statistically significant although nicotine withdrawal symptoms were higher in the 6 vs 18 mg/mL condition (main effect of nicotine) and in the fixed vs adjustable power condition (main effect of power).

*Positive Effects*

There was a significant nicotine x power interaction for positive effects. Post-hoc tests revealed that positive effects were lower in the 6 vs. the 18 mg/mL nicotine condition under fixed power (6F vs. 18F: t19 = -2.96, p = 0.008, mean difference = -11.93, 95% CI = -20.38 – -3.49) and lower under 6F compared with 6A (t19 = -3.74, p = 0.001, mean difference = -13.14, 95% CI = -20.49 – -5.79).

*Negative Effects*

Self-reported adverse effects were very low across conditions and there was no significant nicotine x power interaction. There was a significant main effect of power with higher ratings of adverse effects in the fixed versus the adjustable power condition.

**Biomarkers Analysis**

Results of the biomarker analyse are presented in Table 2.

*Nicotine Delivery (salivary cotinine)*

The interaction between nicotine concentration and power was not statistically significant but there was a main effect of nicotine with higher salivary cotinine levels in the 18 mg/mL compared with the 6 mg/mL nicotine condition. There was also a significant main effect of order with those receiving 18mg/mL first achieving higher overall cotinine levels (F3,15 = 6.54, p = 0.005, ηp2 = 0.57).

*Acrolein (3-HMPA) and Formaldehyde (formate) exposure*

Four urine samples were not received for analysis. For 3-HPMA there was no significant nicotine x power interaction or main effects. There was a significant nicotine x power interaction for formate; levels were higher in the 6A condition compared with all other conditions although these differences were not statistically significant in post hoc t-tests. As the 3-HPMA and formate variables were positively skewed by a few extreme high scores, the analysis was repeated with outliers removed (6 in each case). The results remained unchanged for 3-HPMA. For formate the interaction remained significant (F1,12 = 13.33, p = 0.003, ηp2 = 0.53) and post-hoc tests revealed a significant difference between 6A and 18A (t12 = 3.16, p = 0.008, mean difference = 4.93, 95% CI = 1.53 – 8.33) although the 6A vs 6F difference fell short of the adjusted level of significance ( t12 = -2.41, p = 0.03, mean difference = -2.77, 95% CI = -5.27 – -0.27).

**Discussion**

Our study is the first to document real world compensatory behaviour (puffing patterns and changes to power) with low nicotine concentration e-liquid and to explore the effects on nicotine intake and toxicant/carcinogen exposure. Consistent with our hypothesis and earlier laboratory study [12], participants increased their puff number and puff duration, decreased their IPI and consumed more e-liquid in the low (6 mg/mL) compared with the high (18 mg/mL) nicotine condition. The effect of nicotine on puff duration was more pronounced when power settings were fixed. Despite this evidence of compensatory behaviour, nicotine intake (measured via salivary cotinine) remained higher in the high nicotine condition. Urge to vape and nicotine withdrawal symptoms were higher, and positive effects were lower in the low nicotine condition, particularly when the power was fixed. When changes to power settings were permitted, participants increased the voltage to a greater extent in the low compared with the high nicotine condition. Whilst acrolein levels did not differ across conditions, formaldehyde exposure was higher in the low nicotine, adjustable power condition. Overall our findings add to the evidence base supporting compensatory behaviour with lower nicotine concentration e-liquid which results in reduced positive subjective effects and may increase formaldehyde exposure.

Our puffing topography findings are consistent with our earlier lab-based study which also found increased puff number and puff duration with a lower nicotine concentration e-liquid [12] supporting the notion that, as with tobacco smokers, vapers engage in compensatory puffing in an attempt to self-titrate with a lower nicotine concentration e-liquid. We also permitted changes to power settings to reflect how experienced vapers using newer-generation devices behave in real-world conditions. Participants were more likely to increase the power in the low nicotine condition resulting in a shorter puff duration (but no change to puff number) compared with fixed power settings. Nevertheless, nicotine intake remained higher in the high nicotine condition regardless of whether power was fixed or not, suggesting that compensatory puffing and changes to power were not adequate to raise nicotine intake to the level achieved via a high (18 mg/mL) nicotine e-liquid concentration. In fact, baseline salivary cotinine levels fell roughly mid-point between the levels achieved in the high and low nicotine conditions suggesting that, as with tobacco smoking and with vapers in our earlier study, upwards and downwards self-titration is incomplete [12,16, 32].

In relation to subjective effects, urge to vape, strength of urges and withdrawal symptoms were higher, and positive effects were lower, in the low nicotine condition. Although urge to vape was unaffected by changes to power-settings, withdrawal symptoms and positive effects were improved suggesting that increasing the power to the battery can improve the subjective experience when using a lower nicotine concentration e-liquid. Nevertheless, although the device used here, as with many newer generation devices, allows adjustment to the power, many standard cigalike and second generation devices do not. Our sample were experienced vapers, many of whom (40%; 8/20) reported sub-ohming and were therefore familiar with changing device settings. In the absence of knowledge or mechanisms to adjust power, our findings suggest that a lower nicotine concentration e-liquid is associated with higher urges and withdrawal symptoms and reduced overall satisfaction.

Levels of 3-HPMA did not differ across nicotine or power conditions and were within the range found in exclusive e-cigarette users in other studies [23, 25] although slightly higher than those reported by Shahab et al. [26]. To our knowledge, we are the first to measure formate as an estimate of formaldehyde exposure, a known human carcinogen [33] in e-cigarette users. Levels of formate were higher in the low versus the high nicotine condition, particularly when users were permitted to adjust the power. These findings are consistent with our previous report of increased formaldehyde in e-cigarette aerosol generated using a more intensive puffing regimen [34]. Although these results are suggestive of an effect of compensatory behaviour on formaldehyde exposure, they are by no means conclusive; the sample size was small and the influence of other foods and drugs (not measured here) known to influence formaldehyde exposure cannot be ruled out.

There are several limitations of our study. Although participants were not aware of the study aims, they were not blinded to the nicotine e-liquid concentration which may have influenced their puffing patterns and subjective reporting. In terms of compliance, reports of using non-study devices was reported occasionally and days of non-use occurred (e.g. during a flight or hospital admission). Although these days were removed from the puffing analysis, this could have influenced the biomarkers analysis. Occasional smoking (including marijuana or hookah use) may also have occurred; although CO levels were all below 10ppm, several were between 6 and 9 ppm and we did not have the resources to biochemically confirm lack of marijuana use. However, cross-referencing these higher CO values against nicotine, 3-HPMA and formate results did not reveal higher levels compared with the rest of the sample. Our participants were all experienced e-cigarette users, had vaped on average for two years and 40% reported sub-ohming. The puffing patterns and behaviour of these users may not therefore reflect the typical vaper or smokers who have recently transitioned to vaping. Finally, vapers are unlikely to transition directly from a very high (18 mg/mL) to a very low (6 mg/mL) nicotine concentration and in practice may move through an intermediate stage (12 mg/mL). Whether smaller changes in nicotine concentrations are associated with changes to puffing topography and subjective effects is unknown.

In conclusion, use of a lower nicotine concentration e-liquid is associated with compensatory puffing, reduced subjective effects and where permitted, increases to the power of the device. Our findings suggest that this compensatory behaviour is not sufficient to fully compensate for lower nicotine delivery and may be associated with increased formaldehyde exposure. Switching to a lower nicotine concentration e-liquid may therefore be unsatisfying, triggering compensatory behaviour which increases e-liquid consumption and may increase health risks. Although our formaldehyde findings require replication, our data suggest that vapers should carefully consider switching to lower nicotine concentration e-liquids.

**Acknowledgements**

The authors wish to acknowledge the support of Cancer Research UK (C50878/A21130)

**References**

1. Vardavas, C. I., Filippidis, F. T., & Agaku, I. T. Determinants and prevalence of e-cigarette use throughout the European Union: A secondary analysis of 26 566 youth and adults from 27 Countries. *Tobacco Control*. 2015;24:442-448.http://doi.org/10.1136/tobaccocontrol-2013-051394
2. Coleman, B. N., Rostron, B., Johnson, S. E., Ambrose, B. K., Pearson, J., Stanton, C. A., … Hyland, A. Electronic cigarette use among US adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013–2014. *Tobacco Control*. 2017 Dec; 26(e2), e117 LP-e126. Retrieved from http://tobaccocontrol.bmj.com/content/26/e2/e117.abstract
3. Action on Smoking and Health (ASH). Use of e-cigarettes (vapourisers) among adults in Great Britain.  London, UK: ASH; 2017.
4. Brown J, Beard E, Kotz D, Michie S, West R. Real‐world effectiveness of e‐cigarettes when used to aid smoking cessation: a cross‐sectional population study. *Addiction*. 2014 Sep 1;109(9):1531-40.
5. Zhu SH, Zhuang YL, Wong S, Cummins SE, Tedeschi GJ. E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys. *BMJ*. 2017 Jul 26;358:j3262.
6. Hartmann‐Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for smoking cessation. The Cochrane Library. 2016 Sep 14.
7. Lopez AA, Hiler MM, Soule EK, Ramôa CP, Karaoghlanian NV, Lipato T, Breland AB, Shihadeh AL, Eissenberg T. Effects of electronic cigarette liquid nicotine concentration on plasma nicotine and puff topography in tobacco cigarette smokers: a preliminary report. *Nicotine Tob Res*. 2015 Sep 16;18(5):720-3.
8. Hajek P, Przulj D, Phillips A, Anderson R, McRobbie H. Nicotine delivery to users from cigarettes and from different types of e-cigarettes. *Psychopharmacology*. 2017 Mar 1;234(5):773-9.
9. Talih S, Balhas Z, Eissenberg T, Salman R, Karaoghlanian N, El Hellani A, Baalbaki R, Saliba N, Shihadeh A. Effects of user puff topography, device voltage, and liquid nicotine concentration on electronic cigarette nicotine yield: measurements and model predictions. *Nicotine Tob Res*. 2015 Feb; 3;17(2):150-7.
10. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. *Scientific Reports*. 2014 Feb 26;4.
11. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. *Psychopharmacology*. 2014 Jan 1;231:401-7.
12. Dawkins LE, Kimber CF, Doig M, Feyerabend C, Corcoran O. Self-titration by experienced e-cigarette users: blood nicotine delivery and subjective effects. *Psychopharmacology*. 2016 Aug 1;233(15-16):2933-41.
13. Etter JF. A longitudinal study of cotinine in long-term daily users of e-cigarettes. *Drug Alcohol Depend*. 2016 Mar 1;160:218-21.
14. Farsalinos K, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Evaluating Nicotine Levels Selection and Patterns of Electronic Cigarette Use in a Group of “Vapers” Who Had Achieved Complete Substitution of Smoking. *Substance Abuse: Research & Treatment*. 2013:7 139–146.
15. Ramôa CP, Hiler MM, Spindle TR, Lopez AA, Karaoghlanian N, Lipato T, Breland AB, Shihadeh A, Eissenberg T. Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report. *Tobacco Control*. 2015 Aug 31:tobaccocontrol-2015
16. Ashton H, Stepney R, Thompson JW. Self-titration by cigarette smokers. *BMJ*. 1979 Aug 11;2:357-60.
17. Ashton H, Watson DW. Puffing frequency and nicotine intake in cigarette smokers. *BMJ*. 1970 Sep 19;3:679-81.
18. Hammond D, Fong GT, Cummings KM, Hyland A. Smoking topography, brand switching, and nicotine delivery: results from an in vivo study. *Cancer Epidemiology and Prevention Biomarkers*. 2005 Jun 1;14:1370-5.
19. Russell MA. Nicotine intake and its regulation. *Journal of Psychosomatic Research*. 1980 Dec 31;24:253-64.
20. Scherer G, Lee PN. Smoking behaviour and compensation: a review of the literature with meta-analysis. *Regulatory Toxicology and Pharmacology*. 2014 Dec 31;70(3):615-28.
21. Farsalinos, K. E., Poulas, K., & Voudras, V. Changes in puffing topography and nicotine consumption depending on the power setting of electronic cigarettes. *Nicotine and Tobacco Research*. 2017 Oct. https://doi.org/10.1093/ntr/ntx219/4318827/Changes-in-puffing-topography-and-nicotine
22. Kośmider L, Sobczak A, Fik M, Knysak J, Zaciera M, Kurek J, Goniewicz ML. (2014). Carbonyl compounds in electronic cigarette vapors—effects of nicotine solvent and battery output voltage. *Nicotine Tob Res*. 16: 1319-1326.
23. Hecht SS, Carmella SG, Kotandeniya D, Pillsbury ME, Chen M, Ransom BW, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. *Nicotine Tob Res*. 2015;17:704-9.
24. Goniewicz ML, Gawron M, Smith DM, Peng M, Jacob P, Benowitz NL. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. *Nicotine Tob Res*. 2017 Feb 1;19:160-7.
25. McRobbie H, Phillips A, Goniewicz ML, Smith KM, Knight-West O, Przulj D, Hajek P. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. *Cancer Prevention Research*. 2015 Sep 1;8:873-8.
26. Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, Feng J, Wang L, West R. Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy UsersA Cross-sectional StudyE-Cigarettes and Toxin Exposure. *Annals of Internal Medicine*. 2017 Mar 21;166:390-400.
27. Cox S, Kośmider L, McRobbie H, Goniewicz M, Kimber C, Doig M, Dawkins L. E-cigarette puffing patterns associated with high and low nicotine e-liquid strength: effects on toxicant and carcinogen exposure. *BMC Public Health*. 2016 Sep 20;16:999.
28. Bernert JT, Jacob P, Holiday DB, Benowitz NL, Sosnoff CS, Doig MV, Feyerabend C, Aldous KM, Sharifi M, Kellogg MD, Langman LJ. Interlaboratory comparability of serum cotinine measurements at smoker and nonsmoker concentration levels: a round-robin study. *Nicotine Tob Res*. 2009 Nov 23;11(12):1458-66.
29. Hopner T, Knappe J. Formate determination with formate dehydrogenase. In: Bergmeyer HU editor. Methods of Enzymatic Analysis 2nd ed. Vol. 3; 1551-1555. Verlag Chemie; New York Academic Press*,* 1974.
30. Foulds, J., Veldheer, S., Yingst, J., Hrabovsky, S., Wilson, S. J., Nichols, T. T., & Eissenberg, T. Development of a questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking e-cigarette users. *Nicotine and Tobacco Research*. 2015 Feb 17(2), 186–192. https://doi.org/10.1093/ntr/ntu204
31. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology*. 2004 Dec 1;177(1-2):195-9
32. Russell MA, Wilson C, Patel UA, Feyerabend C, Cole PV. Plasma nicotine levels after smoking cigarettes with high, medium, and low nicotine yields. *BMJ*. 1975 May 24;2(5968):414-6.
33. Food and Drug Administration. Harmful and potentially harmful constituents in tobacco products and tobacco smoke: Established list, 2012. Available from: <https://www.fda.gov/tobaccoproducts/guidancecomplianceregulatoryinformation/ucm297786.htm>
34. Kośmider L,Kimber CF, Kurek J, Corcoran O, Dawkins LE. Compensatory puffing with lower nicotine concentration e-liquid increases carbonyl exposure in e-cigarette aerosols. *Nicotine Tob Res*. 2017 Jul 22. ntx162, <https://doi.org/10.1093/ntr/ntx162>

**Tables and Figures with Legend**

**Table 1** *Participant Demographics and Baseline Characteristics*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **N** | **Percent.** | **Mean** | **SD** | **Min** | **Max** |
| **Gender** |  |  |  |  |  |  |
| Male | 12 | 60 |  |  |  |  |
| Female | 8 | 40 |  |  |  |  |
|  |  |  |  |  |  |  |
| **Age (years)** | 20 |  | 37.90 | 10.66 | 23 | 62 |
|  |  |  |  |  |  |  |
| **Ethnicity** |  |  |  |  |  |  |
| White | 19 | 95 |  |  |  |  |
| Mixed-race | 1 | 5 |  |  |  |  |
|  |  |  |  |  |  |  |
| **Qualification** |  |  |  |  |  |  |
| GSCEs level | 10 | 50 |  |  |  |  |
| A levels | 5 | 25 |  |  |  |  |
| Undergraduate level (5 to 6) | 2 | 10 |  |  |  |  |
| Post-graduate level (7 and above) | 3 | 15 |  |  |  |  |
|  |  |  |  |  |  |  |
| **Occupational status** |  |  |  |  |  |  |
| Employed | 14 | 70 |  |  |  |  |
| Retired | 1 | 5 |  |  |  |  |
| Self-employed | 5 | 25 |  |  |  |  |
|  |  |  |  |  |  |  |
| **Length of time quit smoking**  **(months)** | 20 |  | 25.95 | 23.35 | 3 | 108 |
|  |  |  |  |  |  |  |
| **E-cig addiction (0-100%)** | 20 |  | 70.15 | 21.90 | 40 | 100 |
| **Penn State E-cig dependence index** | 20 |  | 12.05 | 4.02 | 4 | 20 |
|  |  |  |  |  |  |  |
| **Baseline cotinine levels (ng/mL)** | 20 |  | 324 | 219 | 39 | 719 |
| **Baseline CO levels** | 19 |  | 3.90 | 2.77 | 0 | 9 |
|  |  |  |  |  |  |  |
| **Daily Liquid Vol consumed (mL)** | 16 |  | 6.57 | 3.10 | 1.3 | 10 |
| **Estimated puffs per day** | 6 |  | 180 | 80 | 80 | 300 |
|  |  |  |  |  |  |  |
| **Current model most used** |  |  |  |  |  |  |
| Rechargeable non-cigalike (2nd gen) | 12 | 60 |  |  |  |  |
| Modular systems (incl.sub-ohms) | 8 | 40 |  |  |  |  |
|  |  |  |  |  |  |  |
| **Main nicotine concentration used** |  |  |  |  |  |  |
| Non-sub-ohmers | 5 | 25 | 14.13 | 4.16 | 6 | 24 |
| Sub-ohmers | 15 | 75 | 8.40 | 4.93 | 3 | 15 |
|  |  |  |  |  |  |  |

**Table 2:** *Mean puffing patterns, product use, subjective effects and biomarker levels across the four conditions*

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **6mg/mL fixed power** | | **18mg/mL fixed power** | | **6mg/mL adjustable power** | | **18mg/mL adjustable power** | | **Nicotine** | **Power** | **Nicotine x Power** |
|  | Mean | SD | Mean | SD | Mean | SD | Mean | SD | F (p) | F (p) | F (p) |
| **Puffing Topography** | | | | | | | | | | | |
| Daily puff number | 338 | 161 | 279 | 127 | 308 | 135 | 272 | 128 | 16.39  (0.001) | 2.16  (0.16) | 0.98 (0.34) |
| Puff Duration | 4.46 | 1.22 | 3.61 | 0.97 | 3.81 | 1.11 | 3.91 | 1.44 | 18.30  (0.001) | 1.69  (0.21) | 12.12  (0.003) |
| Inter-puff Interval | 34.22 | 20.08 | 41.22 | 26.23 | 39.32 | 26.80 | 37.32 | 27.18 | 0.33  (0.58) | 0.04  (0.86) | 5.76  (0.03) |
| **Product Use** | | | | | | | | | | | |
| Daily (mL) liquid consumed | 6.19 | 3.74 | 4.63 | 2.13 | 5.79 | 3.63 | 4.79 | 2.35 | 6.25  (0.02) | 0.07  (0.80) | 0.75  (0.40) |
| Voltage (wattage) | 4 (10) | - | 4 (10) | - | 4.5 (12.66) | 0.7 | 4.3  (11.56) | 0.8 | - | - | - |
| **Subjective Effects** | | | | | | | | | | | |
| Urge to vape | 3.20 | 1.11 | 2.40 | 0.10 | 3.00 | 0.86 | 2.45 | 0.83 | 16.74  (0.001) | 0.77  (0.39) | 1.95  (0.18) |
| Strength of urges | 2.90 | 1.17 | 2.15 | 0.67 | 2.85 | 1.18 | 2.45 | 1.10 | 14.63  (0.001) | 0.91  (0.36) | 3.56  (0.08) |
| Withdrawal symptoms | 9.05 | 4.56 | 7.80 | 2.59 | 7.45 | 2.91 | 6.80 | 1.36 | 4.88  (0.04) | 8.78  (0.01) | 2.51  (0.13) |
| Positive Effects | 50.71 | 19.82 | 62.64 | 20.30 | 63.85 | 21.58 | 63.42 | 22.25 | 2.06  (0.17) | 4.69  (0.05) | 26.48  (0.001) |
| Negative Effects | 15.05 | 19.49 | 22.25 | 22.75 | 11.26 | 9.66 | 14.74 | 12.84 | 3.37  (0.09) | 5.36  (0.03) | 0.38  (0.55) |
| **Biomarkers** | | | | | | | | | | | |
| Salivary Cotinine (ng/mL) | 250.45 | 188.23 | 402.52 | 190.00 | 274.95 | 172.81 | 405.21 | 192.80 | 17.49  (0.001) | 0.15  (0.70) | 0.12  (0.73) |
| 3-HPMA (ng/mg creatinine) | 211.83 | 133.09 | 262.73 | 202.50 | 224.13 | 343.39 | 378.35 | 467.35 | 0.82  (0.38) | 0.29  (0.60) | 0.09  (0.77) |
| Formate (µg/mg creatinine) | 10.52 | 8.00 | 9.62 | 7.28 | 18.01 | 23.56 | 7.61 | 7.24 | 4.58  (0.05) | 1.88  (0.19) | 6.92  (0.02) |